Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

Summary

The purpose of this research study is to determine the effectiveness of adding deucravacitinib to the participant's current Psoriatic Arthritis (PsA) treatment to see if it improves their symptoms and quality of life. This study is exploring a new treatment approach that may help improve control of psoriatic disease by targeting different parts of the disease process. By combining therapies that work together, the goal is to offer better symptom relief with fewer or more manageable side effects than some current treatments.

Timeline

Start

2026-04-15

Primary completion

2027-12-15

Completion

2027-12-15

Drugs

Indications